BioElectronics, Lahey Clinic to study ActiPatch for soft tissue injuries

By Lisa Kerner

Erie, Pa., March 21 - BioElectronics Corp. and Lahey Clinic agreed to a three-year program to study the effects of ActiPatch on a variety of soft tissue injuries and related medical conditions.

ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy to reduce pain and swelling, according to a company news release.

The Lahey Clinic of Boston will start a number of double-blind clinical studies on ActiPatch in the areas of plastic surgery, orthopedics and chronic wound care.

Trial results will be submitted to the Food and Drug Administration for expanded indications for the use of ActiPatch.

The ActiPatch clinical program will be spearheaded by Lahey Clinic's chairman of the department of plastic surgery, Dr. Jeffrey Weinzweig, officials said.

"We are thrilled and quite fortunate to have a partnership with a medical research institution of the caliber of the Lahey Clinic," BioElectronics executive president and chief executive officer Andrew J. Whelan said in the release.

"The talents of the Lahey team greatly enhance our mission in the clinical study of our breakthrough technology."

BioElectronics, based in Frederick, Md., miniaturizes therapeutic applications into disposable, cost-effective dermal patches.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.